(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay - 2Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- 3Instructions to Pick the Right Dental Expert for Teeth Substitution
- 4Holiday rom-com meets football fever — are Hallmark and NFL fans secretly the same audience?
- 5Remote Work Survival reference: Helping Efficiency at Home
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- New subclade K flu strain raises concerns: What families should know
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- US FDA approves Kura-Kyowa's blood cancer therapy
- Vote in favor of your Favored kind of pasta
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- 5 Cell phones of the Year
- 10 Hints for a Fruitful New employee screening
- Sweet Taste? Candy Fulfills You
